0001804176False00018041762025-02-282025-02-280001804176us-gaap:CommonStockMember2025-02-282025-02-280001804176us-gaap:WarrantMember2025-02-282025-02-28

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 28, 2025
Butterfly Network, Inc.
(Exact name of registrant as specified in its charter)
Delaware001-3929284-4618156
(State or other jurisdiction of
incorporation)		(Commission File Number)(IRS Employer
 Identification No.)
1600 District Avenue
Burlington, MA
01803
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (781) 557-4800
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Class A common stock, par value $0.0001 per shareBFLYThe New York Stock Exchange
Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per shareBFLY WSThe New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company         ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 2.02. Results of Operations and Financial Condition.
On February 28, 2025, Butterfly Network, Inc. (the “Company”) issued a press release announcing its results for the fourth quarter and year ended December 31, 2024 and providing a business update. A copy of the press release is furnished as Exhibit 99.1 hereto.
The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
Exhibit No.Description
99.1
104Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BUTTERFLY NETWORK, INC.
By:/s/ Heather C. Getz, CPA
Name:Heather C. Getz, CPA
Title:Executive Vice President and Chief Financial & Operations Officer
Date: February 28, 2025

Exhibit 99.1

Butterfly Network Reports Fourth Quarter 2024 Financial Results
Delivered Record Annual and Quarterly Revenue

•Delivered quarterly record Revenue of $22.4 million in Q4, representing 35% YoY growth
•Reduced Q4 Net Loss by 59% and Net Cash Used in Operations by 76%
•Successful public offering closed on January 31, 2025 with $81.7 million of net proceeds
BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE) -- Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly” or the “Company”), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, today announced financial results for the fourth quarter and year ended December 31, 2024, and provided a business update.
Joseph DeVivo, Butterfly's President, Chief Executive Officer and Chairman commented, “2024 was a year of focused execution against the strategy we introduced at our March 2024 Investor Day. With 25% topline growth, high-impact product launches and key milestones achieved, we completed a strong first year of the five-year plan and put programs in place to accelerate growth across our core point-of-care ultrasound business, as well as Octiv™ and Butterfly HomeCare.”
DeVivo continued, “As we enter 2025, Butterfly steps into its next era. With strong revenue momentum, a successful capital raise, and a reinforced financial position, we have the ability to invest in strategic initiatives while maintaining a clear path to cash flow independence. We are advancing our vision of making AI-powered, point-of-care ultrasound more accessible – putting our technology into the hands of doctors, nurses, and eventually, qualified chronic care patients worldwide. With control over our future, we are well-positioned to scale in 2025 and beyond.”
Recent Operational and Strategic Highlights:
•New Clinical Evidence: Published preliminary findings from seminal study with Rutgers Robert Wood Johnson Medical School, demonstrating significant reductions in length of stay and healthcare costs for congestive heart failure management when using Butterfly devices in hospital settings.
•Successful Capital Raise: Public offering closed on January 31, 2025 with $81.7 million of net proceeds, including the shoe. This funding further strengthens Butterfly’s balance sheet, as well as its ability to drive innovation to expand access to advanced imaging technology.
•Butterfly HomeCare Progress:
◦Initiated pilot for virtual chronic care management with a leading Medicare Advantage provider, training nurse practitioners to use AI-guided lung ultrasound for congestive heart failure patients in long-term care facilities. Early results are promising, with no hospital readmissions and timely interventions improving care.
◦Completed successful proof of concept with myPlace Health, a PACE (Program of All-inclusive Care for the Elderly) organization, which demonstrated the ability to identify undiagnosed conditions and support risk scoring for reimbursement.
•New Octiv™ Partnerships: Named third partner, Sonic Incytes, developing a novel approach to liver disease assessment, and signed two additional new partners in the Neuroscience and Generative AI space – all expected to drive 2025 revenue.
•Butterfly Garden Growth: Signed four new AI development partners in the fourth quarter, including the first Veterinary AI partnership, bringing the portfolio to 21 companies.


•European Union’s Restriction of Hazardous Substances (RoHS) Update: Following Butterfly’s revocation submission in October 2024, the EU commission is now identifying a third party to review the petition, with a recommendation expected by the end of 2025. If favorable, implementation may take 12-18 months.
Three Months Ended December 31, 2024 Financial Results
Revenue: Total revenue was $22.4 million, up 35% from $16.5 million in the fourth quarter of 2023. U.S. revenue was $14.5 million, up 32% from prior year, driven by the recently launched next-generation iQ3 probe’s higher selling price and increased enterprise software revenue. International revenue increased 19% year-over-year to $5.5 million, with new geographies contributing revenue. Other revenue contributed $2.4 million.
•Product revenue was $14.7 million, an increase of 45% versus the prior year period, driven by the 22% increase in units fulfilled year-over-year and the iQ3’s higher selling price.
•Software and other services revenue was up 20% year-over-year at $7.6 million. Software and other services mix was 34% of revenue and decreased by 4 percentage points versus the prior year due to the higher product revenue achieved this quarter.
Gross profit: Gross profit was $13.7 million versus a gross loss of $12.5 million in the prior year period, and adjusted gross profit was $13.7 million versus $9.4 million in the prior period. Gross margin increased to 61.4% from negative 75.9% in the prior year period, and adjusted gross margin increased to 61.4% from 56.6% in the prior year period. This increase was primarily due to a higher average selling price, partially offset by higher amortization which reduced margin by approximately 35 basis points and a lower mix of software and other services revenue.
Operating expenses: Operating expenses were $31.0 million, down 9% from $34.2 million in the prior year period, due to the business transformation initiative to optimize non-specialized technical functions, previously announced reductions in force in the prior year, and non-payroll spending rationalization across all areas. Total operating expenses excluding stock-based compensation and Other expense were $25.4 million, compared to $27.3 million in the fourth quarter of 2023, representing a decrease of 7%.
Net loss: Net loss was $18.1 million, compared to $44.1 million in the prior year period.
Adjusted EBITDA: Adjusted EBITDA loss was $9.1 million, compared to $15.7 million in the prior year period.
Adjusted EPS: Adjusted EPS was $(0.05), compared to $(0.08) in the prior year period.
Cash, cash equivalents, and restricted cash: Cash, cash equivalents, and restricted cash were $92.8 million as of December 31, 2024.
Guidance
Revenue Guidance and Adjusted EBITDA guidance for the Fiscal Year 2025:
•Revenue guidance of $96 million to $100 million or approximately 20% growth
•Adjusted EBITDA guidance loss of $37 million - $42 million
Reconciliation of GAAP to Adjusted
Reconciliations of gross margin to adjusted gross margin and of net loss to adjusted EBITDA and adjusted EPS for the three months and year ended December 31, 2024, and 2023 is provided in the financial schedules that are part of this press release. An explanation of these non-GAAP financial measures is also included below under the heading “Non-GAAP Financial Measures.”


Conference Call
A conference call and webcast to discuss fourth quarter and full year 2024 financial performance and operational progress is scheduled for 8:00 am ET on February 28, 2025. The conference call will be broadcast live in listen-only mode via a webcast on Butterfly’s Investor Relations website at Events & Presentations. Individuals interested in listening to the conference call on your telephone may do so by dialing approximately ten minutes prior to start time:
US domestic callers: 1-877-300-8521
International callers: 1-412-317-6026
Conference ID: 10195836
Or use the Call me™ link for instant online telephone access to the event
(active 15 minutes prior to scheduled start time):
https://callme.viavid.com/?$Y2FsbG1lPXRydWUmcGFzc2NvZGU9JmluZm89Y29tcGFueSZyPXRydWUmYj0xNg==
After the live webcast, the webcast will be archived on Butterfly’s Investor Relations page.
About Butterfly Network
Butterfly Network, Inc. (NYSE: BFLY) is a healthcare company driving a digital revolution in medical imaging with its proprietary Ultrasound-on-Chip™ semiconductor technology and ultrasound software solutions. In 2018, Butterfly launched the world’s first handheld, single-probe, whole-body ultrasound system, Butterfly iQ. The iQ+ followed in 2020, and the iQ3 in 2024, each with improved processing power and performance by leveraging Moore’s Law. The iQ3 earned Best Medical Technology at the 2024 Prix Galien USA Awards, a prestigious honor and one of the highest accolades in healthcare. Butterfly’s innovations have also been recognized by Fierce 50, TIME’s Best Inventions and Fast Company’s World Changing Ideas, among other achievements.
Butterfly combines advanced hardware, intelligent software, AI, services, and education to drive adoption of affordable, accessible imaging. Clinical publications demonstrate that its handheld ultrasound probes paired with Compass™ enterprise workflow software, can help hospital systems improve care workflows, reduce costs, and enhance provider economics. With a cloud-based solution that enables care anywhere through next-generation mobility, Butterfly aims to democratize healthcare by addressing critical global healthcare challenges. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, the Middle East, North America and South America; to learn more about available countries, visit: https://www.butterflynetwork.com/choose-your-country.
Non-GAAP Financial Measures
In addition to providing financial measures based on generally accepted accounting principles in the United States of America (“GAAP”), we provide additional financial measures that are not prepared in accordance with GAAP (“non-GAAP”). The non-GAAP financial measures included in this press release are adjusted gross profit, adjusted gross margin, adjusted EBITDA, and adjusted EPS. We present non-GAAP financial measures in order to assist readers of our financial statements in understanding the core operating results that our management uses to evaluate the business and for financial planning purposes. Our non-GAAP financial measures provide an additional tool for investors to use in comparing our financial performance over multiple periods.
The non-GAAP financial measures included in this press release are key performance measures that our management uses to assess our operating performance. These non-GAAP measures facilitate internal comparisons of our operating performance on a more consistent basis. We use these performance measures for business planning purposes and forecasting. We believe that these non-GAAP measures enhance an investor’s understanding of our financial performance as they are useful in assessing our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business.


The non-GAAP financial measures included in this press release may not be comparable to similarly titled measures of other companies because they may not calculate these measures in the same manner. These non-GAAP financial measures are not prepared in accordance with GAAP and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. When evaluating the Company’s performance, you should consider adjusted gross profit, adjusted gross margin, adjusted EBITDA, and adjusted EPS alongside other financial performance measures prepared in accordance with GAAP, including gross profit, gross margin, net loss, and EPS.
The non-GAAP financial measures do not replace the presentation of our GAAP financial results and should only be used as a supplement to, not as a substitute for, our financial results presented in accordance with GAAP. In this press release, we have provided reconciliations of adjusted gross profit to gross profit, adjusted gross margin to gross margin, and adjusted EBITDA and adjusted EPS to net loss, the most directly comparable GAAP financial measures. Reconciliations of our non-GAAP financial measures to corresponding GAAP measures are not available on a forward-looking basis because we are unable to predict with reasonable certainty the non-cash component of employee compensation expense, changes in our working capital needs, variances in our supply chain, the impact of earnings or charges resulting from matters we consider not to be reflective, on a recurring basis, of our ongoing operations, and other such items without unreasonable effort. These items are uncertain, depend on various factors, and could be material to our results computed in accordance with GAAP. Management strongly encourages investors to review our financial statements and publicly filed reports in their entirety and not to rely on any single financial measure.
Forward Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Our actual results may differ from our expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believe,” “predict,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, our expectations with respect to financial results, future performance, commercialization and plans to deploy our products and services, development of products and services, and the size and potential growth of current or future markets for our products and services. Forward-looking statements are based on our current beliefs and assumptions and on information currently available to us. These forward-looking statements involve significant known and unknown risks and uncertainties and other factors that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside our control and are difficult to predict. Factors that may cause such differences include, but are not limited to: our ability to grow and manage growth effectively; the success, cost, and timing of our product and service development activities; the potential attributes and benefits of our products and services; the degree to which our products and services are accepted by healthcare practitioners and patients for their approved uses; our ability to obtain and maintain regulatory approval for our products, and any related restrictions and limitations of any approved product; our ability to identify, in-license, or acquire additional technology; our ability to maintain our existing license, manufacturing, supply, and distribution agreements; our ability to compete with other companies currently marketing or engaged in the development of products and services that we are currently marketing or developing; changes in applicable laws or regulations; the size and growth potential of the markets for our products and services, and our ability to serve those markets, either alone or in partnership with others; the pricing of our products and services, and reimbursement for medical procedures conducted using our products and services; our estimates regarding expenses, revenue, capital requirements, and needs for additional financing; our financial performance; our ability to raise financing in the future; and other risks and uncertainties indicated from time to time in our most recent Annual Report on Form 10-K or in subsequent filings that we make with the Securities and Exchange Commission. We caution that the foregoing list of factors is not exclusive. We caution you not to place undue reliance upon any forward-looking statements, which speak only as of the date of this press release. We do not undertake or accept any obligation or undertake to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based.


Contacts:
Investors
Heather Getz
Chief Financial and Operations Officer, Butterfly
investors@butterflynetwork.com


BUTTERFLY NETWORK, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share and per share amounts)
(Unaudited)
Three months ended December 31,Year ended December 31,
2024202320242023
Revenue:
Product$14,723 $10,162 $54,200 $40,036 
Software and other services7,628 6,354 27,856 25,864 
Total revenue22,351 16,516 82,056 65,900 
Cost of revenue:
Product6,641 26,889 24,380 40,655 
Software and other services1,976 2,163 8,845 8,389 
Total cost of revenue8,617 29,052 33,225 49,044 
Gross profit (loss)13,734 (12,536)48,831 16,856 
Operating expenses:
Research and development8,826 11,207 37,800 55,616 
Sales and marketing11,854 10,297 41,567 39,073 
General and administrative9,943 12,375 39,810 49,613 
Other426 316 4,065 18,164 
Total operating expenses31,049 34,195 123,242 162,466 
Loss from operations(17,315)(46,731)(74,411)(145,610)
Interest income997 1,736 5,020 7,450 
Interest expense(334)— (1,261)— 
Change in fair value of warrant liabilities(1,033)620 (1,859)4,544 
Other income (expense), net(526)254 (13)(2)
Loss before provision for income taxes(18,211)(44,121)(72,524)(133,618)
Provision (benefit) for income taxes(109)— (32)82 
Net loss and comprehensive loss$(18,102)$(44,121)$(72,492)$(133,700)
Net loss per common share attributable to Class A and B common stockholders, basic and diluted$(0.08)$(0.21)$(0.34)$(0.65)
Weighted-average shares used to compute net loss per share attributable to Class A and B common stockholders, basic and diluted213,389,209207,274,099211,682,760205,385,544


BUTTERFLY NETWORK, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
(Unaudited)
December 31,
20242023
Assets
Current assets:
Cash and cash equivalents$88,775 $134,437 
Accounts receivable, net of allowance for doubtful accounts of $2,583 and $1,787 at December 31, 2024 and December 31, 2023, respectively
20,793 13,418 
Inventories70,789 73,022 
Current portion of vendor advances5,547 2,815 
Prepaid expenses and other current assets6,709 7,571 
Total current assets192,613 231,263 
Property and equipment, net19,518 25,321 
Intangible assets, net8,916 10,317 
Non-current portion of vendor advances15,042 15,276 
Operating lease assets14,233 15,675 
Other non-current assets5,760 6,422 
Total assets$256,082 $304,274 
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$4,250 $5,090 
Deferred revenue, current16,139 15,625 
Accrued purchase commitments, current131 131 
Accrued expenses and other current liabilities27,695 23,425 
Total current liabilities48,215 44,271 
Deferred revenue, non-current7,315 7,394 
Warrant liabilities2,685 826 
Operating lease liabilities20,398 22,835 
Other non-current liabilities8,637 8,895 
Total liabilities87,250 84,221 
Commitments and contingencies
Stockholders’ equity:
Class A common stock $.0001 par value; 600,000,000 shares authorized at December 31, 2024 and December 31, 2023; 188,626,154 and 181,221,794 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively
19 18 
Class B common stock $.0001 par value; 27,000,000 shares authorized at December 31, 2024 and December 31, 2023; 26,426,937 shares issued and outstanding at December 31, 2024 and December 31, 2023
3 3 
Additional paid-in capital970,940 949,670 
Accumulated deficit(802,130)(729,638)
Total stockholders’ equity$168,832 $220,053 
Total liabilities and stockholders’ equity$256,082 $304,274 


BUTTERFLY NETWORK, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
Year ended December 31,
20242023
Cash flows from operating activities:
Net loss$(72,492)$(133,700)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation, amortization, and impairments10,342 10,574 
Non-cash interest expense
1,256 — 
Write-down of inventories15 21,083 
Stock-based compensation expense21,032 27,480 
Change in fair value of warrant liabilities1,859 (4,544)
Gain on lease termination— (214)
Other1,102 633 
Changes in operating assets and liabilities:
Accounts receivable(8,503)(162)
Inventories2,218 (34,135)
Prepaid expenses and other assets1,304 2,979 
Vendor advances(2,498)17,091 
Accounts payable(841)(1,875)
Deferred revenue435 2,206 
Accrued purchase commitments— (2,015)
Change in operating lease assets and liabilities(750)(635)
Accrued expenses and other liabilities3,814 (3,586)
Net cash used in operating activities(41,707)(98,820)
Cash flows from investing activities:
Purchases of marketable securities— (297)
Sales of marketable securities— 76,484 
Purchases of property, equipment, and intangible assets, including capitalized software(2,694)(5,783)
Sales of property and equipment36 10 
Net cash provided by (used in) investing activities(2,658)70,414 
Cash flows from financing activities:
Proceeds from exercise of stock options and warrants64 228 
Proceeds from employee stock purchase plan
495 — 
Payments to tax authorities for restricted stock units withheld
(739)— 
Payments on technology license commitment
(1,315)— 
Net cash provided by (used in) financing activities
(1,495)228 
Net decrease in cash, cash equivalents, and restricted cash
(45,860)(28,178)
Cash, cash equivalents, and restricted cash, beginning of period138,650 166,828 
Cash, cash equivalents, and restricted cash, end of period$92,790 $138,650 
Supplementary disclosure of non-cash investing and financing activities
Acquisition of property, equipment, and intangible assets, including capitalized software$470 $9,247 


BUTTERFLY NETWORK, INC.
ADJUSTED GROSS PROFIT AND ADJUSTED GROSS MARGIN
(In thousands)
(Unaudited)
Three months ended December 31,Year ended December 31,
2024202320242023
Revenue$22,351 $16,516 $82,056 $65,900 
Cost of revenue8,617 29,052 33,225 49,044 
Gross profit (loss)$13,734 $(12,536)$48,831 $16,856 
Gross margin61.4 %(75.9 %)59.5 %25.6 %
Add:
Write-downs and write-offs of inventories— 21,891 97 21,891 
Adjusted gross profit$13,734 $9,355 $48,928 $38,747 
Adjusted gross margin61.4 %56.6 %59.6 %58.8 %
Depreciation and amortization$1,536 $1,458 $6,398 $5,585 
% of revenue6.9 %8.8 %7.8 %8.5 %


BUTTERFLY NETWORK, INC.
ADJUSTED EBITDA AND ADJUSTED EPS
(In thousands, except share and per share amounts)
(Unaudited)
Included on the condensed consolidated statements of operations and comprehensive loss as:Three months ended December 31,Year ended December 31,
2024202320242023
Net lossNet loss$(18,102)$(44,121)$(72,492)$(133,700)
Stock-based compensationR&D, S&M, and G&A5,238 6,556 21,032 27,480 
Write-downs and write-offs of inventoriesCost of revenue— 21,891 97 21,891 
Change in fair value of warrant liabilitiesChange in fair value of warrant liabilities1,033 (620)1,859 (4,544)
OtherOther426 316 4,065 18,164 
Other expense (income), netOther income (expense), net526 (254)13 2 
Adjusted net loss(10,879)(16,232)(45,426)(70,707)
Interest incomeInterest income(997)(1,736)(5,020)(7,450)
Interest expenseInterest expense334 — 1,261 — 
Provision (benefit) for income taxesProvision for income taxes(109)— (32)82 
Depreciation and amortizationCost of revenue, R&D, S&M, and G&A2,507 2,242 10,342 10,574 
Adjusted EBITDA$(9,144)$(15,726)$(38,875)$(67,501)
Adjusted EPS$(0.05)$(0.08)$(0.21)$(0.34)
Weighted average shares used to compute adjusted EPS213,389,209207,274,099211,682,760205,385,544

v3.25.0.1
Cover
Feb. 28, 2025
Document Information [Line Items]  
Document Type 8-K
Document Period End Date Feb. 28, 2025
Entity Registrant Name Butterfly Network, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-39292
Entity Tax Identification Number 84-4618156
Entity Address, Address Line One 1600 District Avenue
Entity Address, City or Town Burlington
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01803
City Area Code 781
Local Phone Number 557-4800
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0001804176
Amendment Flag false
Common stock  
Document Information [Line Items]  
Title of 12(b) Security Class A common stock, par value $0.0001 per share
Trading Symbol BFLY
Security Exchange Name NYSE
Warrant  
Document Information [Line Items]  
Title of 12(b) Security Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share
Trading Symbol BFLY WS
Security Exchange Name NYSE
Butterfly Network (NYSE:BFLY)
과거 데이터 주식 차트
부터 2월(2) 2025 으로 3월(3) 2025 Butterfly Network 차트를 더 보려면 여기를 클릭.
Butterfly Network (NYSE:BFLY)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025 Butterfly Network 차트를 더 보려면 여기를 클릭.